Fate Therapeutics, Inc. (FATE) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Fate Therapeutics, Inc. (FATE) Earnings Overview
As of October 3, 2026, Fate Therapeutics, Inc. (FATE) reported trailing twelve-month net income of -$126M, reflecting +29.9% year-over-year growth. The company earned $-1.05 per diluted share over the past four quarters, with a net profit margin of -2051.1%.
Looking at the long-term picture, FATE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2011.
Fate Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRSP (-$451M net income, -16569.8% margin), NTLA (-$400M net income, -609.9% margin), BEAM (-$85M net income, -57.2% margin), FATE has outperformed on profitability metrics. Compare FATE vs CRSP →
FATE Earnings vs Peers
Earnings metrics vs comparable public companies
FATE Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$136M | +26.8% | -$148M | $-1.15 | -2051.1% | -2222.4% |
| 2024 | -$186M | -15.7% | -$210M | $-1.64 | -1366.5% | -1542.6% |
| 2023 | -$161M | +42.9% | -$191M | $-1.64 | -253.3% | -299.9% |
| 2022 | -$282M | -32.8% | -$308M | $-2.91 | -292.5% | -320.2% |
| 2021 | -$212M | -22.4% | -$217M | $-2.24 | -379.9% | -388.6% |
| 2020 | -$173M | -76.7% | -$128M | $-2.10 | -551.6% | -407.5% |
| 2019 | -$98M | -47.4% | -$101M | $-1.43 | -919.0% | -943.1% |
| 2018 | -$67M | -55.1% | -$67M | $-1.19 | -1405.0% | -1415.4% |
| 2017 | -$43M | -28.4% | -$42M | $-1.02 | -1046.1% | -1025.9% |
| 2016 | -$33M | -11.6% | -$32M | $-1.05 | -760.2% | -726.1% |
| 2015 | -$30M | -15.9% | -$28M | $-1.18 | -1233.7% | -1142.8% |
| 2014 | -$26M | -23.9% | -$25M | $-1.27 | - | - |
| 2013 | -$21M | -46.7% | -$18M | $-1.06 | -2151.8% | -1820.3% |
| 2012 | -$14M | -6.0% | -$14M | $-1.61 | -533.3% | -507.8% |
| 2011 | -$13M | - | -$13M | $-1.51 | -1147.6% | -1136.2% |
Download Data
Export FATE earnings history in CSV or JSON format
Free sign-in required to download data
FATE Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FATE — Frequently Asked Questions
Quick answers to the most common questions about buying FATE stock.
What is FATE earnings per share (EPS)?
FATE trailing twelve-month (TTM) diluted EPS is $-1.05, reflecting +29.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Fate Therapeutics, Inc.'s net income?
Fate Therapeutics, Inc. (FATE) trailing twelve-month net income is $-126M as of 2025. Earnings grew +29.9% year-over-year.
Is FATE profitable?
FATE is not currently profitable on a TTM basis, reporting a net loss of $-126M. Net margin is -2051.1%. Investors should monitor for a return to profitability.
What is FATE's earnings growth rate?
FATE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are FATE's profit margins?
Fate Therapeutics, Inc. net profit margin is -2051.1%, operating margin is -2222.4%, and gross margin is -94.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -51.8%.
Is FATE growing earnings?
Yes, FATE earnings are accelerating — EPS growth of +29.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-126M. Earnings momentum is strengthening.
What was FATE's best earnings year?
Fate Therapeutics, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2011. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were FATE's earnings last quarter?
FATE's most recent reported quarter was Q2 2026. Net income was $-30M with diluted EPS of $-0.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.